Purpose

Most relationships between size and nanomedicine performance and safety were established before the early 2010s’ when batch-mode dynamic light scattering (batch-mode DLS) was the only easy size measurement method for colloids available. They are basis for the rational design of nanomedicines, but misunderstood contrasting results are reported. This work aimed to investigate whether these relationships can be used with confidence knowing that batch-mode DLS can be tricky when measuring sizes of polydisperse systems.

Methods

A polydisperse dispersion of polymer nanoparticles ranging from 100 to 465 nm was synthesized. The particles were separated in 4 fractions by successive centrifugations. The capacity of each fraction and parent dispersion to activate the complement system was evaluated by Crossed immuno-electrophoresis.

Results

Each fraction was a population of particles with a distinct size. It showed a different capacity to activate the complement system. Particles of the fractions showing the strongest capacity to activate the complement systems had a different size evaluated by batch-mode DLS then that of the parent particles.

Conclusion

Particles activating the complement system in the parent dispersion were not those that were detected by batch-mode DLS while measuring its size. This work pointed out that previously established relationships between nanomedicine size and their biological response should be taken with caution if sizes were only measured by batch-mode DLS.

中文翻译：

---

了解纳米药物的大小和生物反应依赖性：仅基于批处理模式DLS测量的大小建立先前关系的相关性是什么？

目的

尺寸与纳米药物性能和安全性之间的大多数关系是在2010年代初期建立的，那时批量模式动态光散射（批量模式DLS）是唯一可用的胶体尺寸简便测量方法。它们是合理设计纳米药物的基础，但据报道误解了对比结果。这项工作旨在调查这些关系是否可以放心使用，因为知道在测量多分散系统的尺寸时，批处理模式DLS可能很棘手。

方法

合成了聚合物纳米粒子在100至465 nm范围内的多分散分散体。通过连续离心将颗粒分成4个部分。通过交叉免疫电泳评估每个级分和母体分散体激活补体系统的能力。

结果

每个部分都是具有不同大小的粒子群。它显示出不同的激活补体系统的能力。显示出最强的激活补体系统能力的级分颗粒具有不同于母体颗粒的通过批处理模式DLS评估的尺寸。

结论

在母体分散体中激活补体系统的颗粒不是通过分批模式DLS在测量其尺寸时检测到的。这项工作指出，如果仅通过分批模式DLS测量尺寸，则应谨慎对待先前建立的纳米药物尺寸与其生物学反应之间的关系。